It is not uncommon, while under general anesthesia, for a patient’s heart to stop beating. In these situations, if a catheter hasn’t been set up to allow the surgery team to manually circulate the patient’s blood, two drugs are available for anesthesiologists to restore the breathing process. Each is effective, but the far less expensive drug, Pronofyl, causes severe allergic reactions in approximately 5% of patients, while the far more expensive drug, Rontynyl – rarely covered by insurance plans – does not cause such reactions. This can put an unfair burden on the surgery teams, however, when these stressful situations occur: in many cases, they must decide for an unconscious patient whether to risk an unlikely-but-catastrophic reaction, or create a potentially disastrous financial situation for the patient.
Which of the following, if true, most strengthens the conclusion above?
(A) All anesthesia providers have equal access to Pronofyl and Rontynyl.
(B) Not all insurance plans will cover the full cost of treatments for allergic reactions to drugs taken while under anesthesia.
(C) The patent for Rontynyl will not expire for several years, so the price of Ronyntyl is not expected to decrease for quite some time.
(D) There is no way to predetermine which patients will have an adverse reaction to Pronofyl.
(E) Patients who receive a dose of Rontynyl often require additional post-operative doctor visits to recover from the drug’s potency.
During the Game of Timers competition, the Quote function is not available. Please use the BIG POST REPLY button or just scroll to the bottom of the discussion to post a reply.